Lonza

Lonza, a pharmaceutical preparation manufacturing company headquartered in Switzerland (CH), reported a total of approximately 2.71 billion kg CO2e in emissions for 2025. This figure encompasses Scope 1, Scope 2, and Scope 3 emissions.

For Scope 1, Lonza's emissions were approximately 317 million kg CO2e. Scope 2 emissions, using market-based accounting, stood at about 93 million kg CO2e, while the location-based figure was approximately 207 million kg CO2e. The majority of Lonza's emissions in 2025, approximately 2.30 billion kg CO2e, stemmed from Scope 3. The most significant contributors within Scope 3 were purchased goods and services (approximately 1.53 billion kg CO2e), followed by processing of sold products (approximately 118 million kg CO2e), and fuel and energy-related activities (approximately 88 million kg CO2e).

In 2024, Lonza reported total emissions of approximately 2.36 billion kg CO2e. This included approximately 343 million kg CO2e for Scope 1 and approximately 1.88 billion kg CO2e for Scope 3.

Lonza has set ambitious climate commitments, including a target to reduce absolute Scope 1 and 2 Greenhouse Gas (GHG) emissions by 42% by 2030, using a 2021 baseline. This target is aligned with the Science Based Targets initiative (SBTi) and aims to keep warming to 1.5°C. The company also aims to achieve net-zero emissions by 2050 or earlier. Lonza is actively working towards these goals, with some targets already showing positive progress. Additional intensity targets include reducing waste by 50% per unit of revenue by 2030 compared to 2018 levels.